The Antimicrobial Resistance (AMR) Working Group is composed of key experts working in the field of antimicrobials and resistance research in the UK, and provides a platform for discussion on the key issues  associated with AMR scientifically, financially and politically. 

AMR Centre

Established in May 2016, the AMR Centre is a key part of the UK’s response to the global threat from Antimicrobial Resistance.

Destiny Pharma

Destiny Pharma is dedicated to the discovery, development and commercialisation of new antimicrobials that have unique properties to improve outcomes for patients and the delivery of medical care into the future.


GSK is a global pharmaceutical company dedicated to helping people feel better, do more and live longer.


LifeArc is the new name for MRC Technology, a medical research charity with a 25 year legacy of helping scientists and organisations turn their research into treatments and diagnostics for patients.

Neem Biotech Ltd

A member of the Zaluvida Group of companies, Wales-based Neem Biotech, established in 1998, engages in R&D for the discovery of unique, safe, natural compounds that have therapeutic properties in human and animal health or applications in agriculture and aquaculture.


NovaBiotics is a leading clinical stage biotechnology company focused on the design and development of first-in-class anti-infective therapies for difficult to treat and poorly served infectious conditions.

Summit (Oxford) Limited

Summit is a UK company focused on the discovery and development of novel drug candidates to treat areas of high unmet medical need.